Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q1 FY26 Earnings Presentation
36 slides from Neuland Laboratories's earnings presentation, Jul 31, 2025
Slide 1: Cover letter to stock exchanges
July 31, 2025 To BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Investors/Analysts
Slide 2: Neuland Laboratories Limited Investor Presentation Q1FY26
Neuland Laboratories Limited Investor Presentation Q1FY26
Slide 3: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Table of Content
Table of Content Q1FY26 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q1FY26 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 5: Q1FY26 Highlights
Q1FY26Highlights 4
Slide 6: Management Commentary
Management Commentary SUCHETH DAVULURI “While Q1 FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of
Slide 7: Business and Financial Highlights
Business and Financial Highlights Q1FY26 Business and Financial Highlights CMS CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years Increasing interest from Biotech's leading to increase in early-stage pro
Slide 8: Q1FY26 Financial Highlights
Q1FY26 Financial Highlights Total Income EBITDA PAT* EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 25.2% 22.1% 28.9% 20.8% 22.5% 101.4 444.4 98.3 79.0 76.6 401.9 17.3% 128.6 10.2% 335.8 315.2 300.6 14.4% 8.3% 90.3 4.6% 65.7 58.2 32.0 24.9 42.1 27.7 21.6 13.7 10.7 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1FY25 Q2F
Slide 9: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE % Fixed Asset Turnover (x) Debt to Equity (x) 32.8% 3.1 2.7 2.4 0.2 2.3 2.1 21.3% 2.1 2.1 17.9% 1.8 1.7 1.6 9.7% 0.1 0.1 0.1 0.1 5.1% FY22 FY23 FY24 FY25 Q1 FY26 FY22 FY23 FY24 FY25 Q1 FY26 FY22 FY23 FY24 FY25 Q1 FY26 FY22 FY23 FY24 FY25 Q1 FY26 Partic
Slide 10: Key Operating Metrics Q1FY26
Key Operating Metrics Q1FY26 Segment revenue Top 10 & Top 5 Products Top 10 & Top 5 Customers Prime Specialty Top 10 Top 10 CMS Others Top 5 Top 5 98% 98% 98% 6% 6% 5% 7% 7% 85% 93% 93% 70% 39% 34% 73% 65% 42% 63% 53% 44% 66% 60% 53% 58% 56% 19% 47% 16% 23% 16% 14% 36% 33% 40% 27% 32% Q1FY25 Q2FY25
Slide 11: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects 170 Q1 FY26 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total API 15 14 13 5 4 9 60 120 Intermediate 5 8 7 4 4 10 38 Grand Total 20 22 20 9 8 19 98 65 14 Q1 FY25 Pre-Clinical P-1 P-2 P-3 Developm
Slide 12: Company Overview
Company Overview 11
Slide 13: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 11,74,000 Liters* Facilities Inspected by Supported 3
Slide 14: Key Facts
Key Facts 40+ 990+ 100+ 82% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 72 1174* KL 1901 Countries Served Active US DMFs API Manufacturing Employees Capacity *- U3 additional capacity commercial production yet to start 13
Slide 15: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Dr. Christopher M. Ms. Pallavi Joshi Rama Mohan Rao Vice Chairman & Vice Chairman & Cimarusti Bhakru Executive Chairman Chief Executive Managing Director Non-executive Independent Officer Director Director Mr. Homi Rustam Mr. Prasad Mr. S
Slide 16: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 Acquisition of Increased flow of projects 100 M+ revenue over Unit – III Crossed INR 10 bn US FDA audit advanced from CMS Japan. 75 live CMS projects Commercialization revenue. of Unit-I intermediates & Active emphasis on supply US FDA audit o
Slide 17: Our Global Presence
Our Global Presence* EUROPE 50% BD office in Lugano, Switzerland Since 2021 APAC NORTH AMERICA 3% 41% BD office in Princeton, New Jersey Since 2004 JAPAN 1% BD office in Tokyo, Japan Since 2007 LATAM INDIA 2% 1% Headquarters in MENA Hyderabad, India 3 Manufacturing 2% Units Manufacturing and Develop
Slide 18: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 258 kL Pashamylaram, Hyderabad 381 kL Gaddapotharam, Hyderabad 536* kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 7 & 8 H
Slide 19: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs of which 3 • Several NCE APIs added in NDA or are for peptides. commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • De
Slide 20: Regulatory Filings
Regulatory Filings 72 32 10 17 25 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 280 ~499 30 993+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Polan
Slide 21: Financial Highlights FY2016-2025
Financial Highlights FY2016-2025 Rs. Cr FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Total Income 511.6 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 EBITDA 81.5 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 EBITDA Margin 15.9% 18.1% 10.2% 9.2% 13.7% 17.1
Slide 22: Business Strategy
Business Strategy 21
Slide 23: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 24: Our Businesses
Our Businesses 23
Slide 25: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 26: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 27: Shareholder Information
Shareholder Information 26
Slide 28: Shareholding Details
Shareholding Details Share Information (as on 30th June 2025) NSE Ticker NEULANDLAB BSE Ticker 524558 Others 34% Market Cap (Rs. Cr) 15,396 Promoters 33% % free-float 67.32% Free-float market cap (Rs. Cr) 10,364 Shares Outstanding 1,28,29,889 3M Average Daily Traded Volume (ADTV) FII DII (Shares)* 5
Slide 29: Annexure
Annexure 28
Slide 30: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars (Rs Cr) Q1FY26 Q1FY25 YoY (%) Q4FY25 QoQ (%) Total Income 300.6 444.4 -32.40% 335.8 -10.50% EBITDA 42.1 128.6 -67.30% 58.2 -27.70% EBITDA Margin 14.00% 28.90% -1490 bps 17.30% -330 bps Exceptional Item* - 20.6 - - - Profit Before Tax* 17.4 130.3 -86.60
Slide 31: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 444 415 421 402 395 390 365 315 336 294 301 258 257 270 238 222 203 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 PBT* 130 128 121 110 104 92 84 53 49 39 39 28 24 12 18 13 17 Q1FY22 Q2FY22 Q3FY
Slide 32: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 33: Global peptide API market is poised to reach $94Bn by 2034
Global peptide API market is poised to reach $94Bn by 2034 Global peptide therapeutic /API market in $Bn Key market drivers Peptide therapeutic 38 117 Peptide API market is expected to grow at a market 22.4% CAGR by 2034 due to growing prevalence of chronic disorders such as diabetes and obesity dri
Slide 34: Sustainability Framework
Sustainability Framework Our Key Goals (included in our Executives’ and Focus Our Priorities Our Commitments Goal Area Leaders’ Balanced Scorecard) • Effluent and Waste3’4 • Reduction in direct emissions Direct emissions • FY35: Carbon neutrality: 30%* reduction • Water3’4 • Efforts to water neutral
Slide 35: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 36: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: ir@Neulandlabs.com Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com